WWW - Posts tagged Taxus stent at BloggingStocks

taxus stent posts

Closing Bell: From Flash-Crash to Flash Dance (BSX, CSCO, MS, GS, BIDU, HBAN, NBG)

Posted May 12th 2010 4:00PM by Jon Ogg (RSS feed)
Filed under: Cisco Systems (CSCO), Boston Scientific (BSX), Goldman Sachs Group (GS), Morgan Stanley (MS)

Trade deficits, record government budget deficits... Humbug! Today was a day where bad news did not matter in the broader sense. Overseas markets were up, but the U.S. was where the action was.

Here were the unofficial closing bell levels:

Dow 10,896.91 +148.65 (1.38%)
S&P 500 1,171.67 +15.88 (1.37%)
Nasdaq 2,425.02 +49.71 (2.09%)

Top Analyst Calls

Continue reading Closing Bell: From Flash-Crash to Flash Dance (BSX, CSCO, MS, GS, BIDU, HBAN, NBG)

Closing Bell: When rising bond yields hurt stocks (BAC, BSX, GM, PG, SNDK)

Posted May 27th 2009 4:00PM by Jon Ogg (RSS feed)
Filed under: General Motors (GM), Bank of America (BAC), Boston Scientific (BSX), Procter and Gamble (PG), SanDisk Corp (SNDK)

Despite Moody's claiming the US's Triple-A rating was stable, the markets sold off today. The markets tried to hold up but the afternoon session was marked by selling as bond yields rose on the long-end of the curve. The 10-Year Treasury yield was up 20 basis points to 3.697% and the 30-Year Treasury yield was up 16 basis points to 4.60%.

Here were the unofficial closing bell levels:

Dow 8,300.98 -172.51 (-2.04%)
S&P 500 893.13 -17.20 (-1.89%)
Nasdaq 1,731.08 -19.35 (-1.11%)

Top Analyst Upgrades
Top Analyst Downgrades

Continue reading Closing Bell: When rising bond yields hurt stocks (BAC, BSX, GM, PG, SNDK)

Abbott Labs stent trial results lift stock

Posted Mar 26th 2007 1:23PM by Brent Archer (RSS feed)
Filed under: Major Movement, Analyst Reports, Good news, Products and Services, Abbott Laboratories (ABT), Boston Scientific (BSX), Options, Technical Analysis

Abbott Laboratories (NYSE: ABT) opened at $55.08. So far today, the stock has hit a low of $55.05 and a high of $56.18. As of 1:20, ABT is trading at $56.41, up $2.55 (4.7%).

The stock is hitting a new 52-week high today after a study showed that Abbott's Xience heart stent performed better than competitor Boston Scientific's (NYSE: BSX) Taxus stent. In addition, two analysts have reiterated their buy ratings for ABT today. The technical indicators for ABT have been bullish but deteriorating, while S&P gives the stock a positive 4 STARS (out of 5) buy rating.

For a bullish hedged play on this stock, I would consider an August bull-put credit spread below the $50 range. ABT hasn't been below $50 since January and has shown support around $53 recently. This trade could be risky if the mid-April earnings for ABT disappoint, but even if the stock dips a little, it looks like it might find support around its 50 day moving average.

Brent Archer is an options analyst and writer at Investors Observer (Free Subscription). DISCLOSURE: Mr. Archer owns and/or controls diversified portfolios of long and short stock and option positions that may include holdings in companies he writes about.